Researchers from Kexing Biopharm Co. Ltd. have published details on the development and preclinical characterization of GB18-06, a novel nanobody, also known as variable domain of heavy-chain antibody ...

Preliminary results from a trial demonstrated that Science Corp.’s Prima retina implant restored ‘form vision,’ including the ...

It’s a go for the two phase III Ensure studies of Immunic Inc.’s lead asset in treating relapsing multiple sclerosis. An ...

Cureverse Inc. and Angelini Pharma SpA signed a potential $360 million deal for CV-01, an oral small-molecule candidate for ...